DSUVIATM (sufentanil): The First Sublingual Formulation of Sufentanil

DSUVIATM (sufentanil):
The First Sublingual Formulation of Sufentanil

For patients with acute pain severe enough to require an opioid, DSUVIA offers a noninvasive option when opioids are needed in a medically supervised setting.  

You're invited to learn more about DSUVIA, the first sublingual formulation of sufentanil.  This program will cover the:

• Clinical opportunity for noninvasive opioid analgesic
• Noninvasive sublingual administration of DSUVIA
• Pharmacokinetics and pharmacodynamics of the single, fixed-dose DSUVIA
• Demonstrated efficacy and safety of DSUVIA in adults with moderate-to-severe acute pain

For additional information regarding this event, please contact Catherine Alto at 703-217-4178 or calto@acelrx.com.

Please register online here: http://www.acelrxprograms.com

Registration Code: 12129SR75

Click here to download the full invitation.